Table 1. Demographic and Clinical Features of the Patient Population.
| Characteristic | Value |
|---|---|
| Sex, No. (%) | |
| Male | 8 (40) |
| Female | 12 (60) |
| Age, mean (SD) [range], y | 46 (13) [16-67] |
| Smoking habits, No. (%) | |
| Smoker | 5 (25) |
| Ex-smoker | 2 (10) |
| Nonsmoker | 13 (65) |
| Thyroid treatment, No. (%) | |
| Methimazole | 3 (15) |
| Radioiodine | 10 (50) |
| Thyroidectomy | 6 (3) |
| None | 1 (5) |
| FT3, mean (SD) [range], pg/dL | 0.38 (0.04) [0.32-0.47] |
| TSH, median (IQR) [range], μU/mL | 0.6 (0.1-1.9) [0.003-4.2] |
| TRAbs, median (IQR) [range], U/L | 3.9 (2.3-5.7) [0.3-9.8] |
| GO duration, median (IQR) [range], mo | 34 (18-51) [2-85] |
| Indication for OD, No. (%) | |
| Optic neuropathy | 3 (15) |
| Severe proptosis | 17 (85) |
| GO treatment, No. (%) | |
| Intravenous GC and radiotherapy | 4 (20) |
| Intravenous GC alone | 11 (55) |
| Oral GC and radiotherapy | 1 (5) |
| None | 4 (20) |
| Months since last GC administration, median (IQR) [range] | 4 (3-18.5) [0-36] |
| Exophthalmometry, mean (SD) [range], mm | 24.6 (2.7) [17-28] |
| Clinical activity score, median (IQR) [range]a | 4 (3-5) [1-7] |
| Diplopia (Gorman score), No. (%) of patients | |
| Absent | 8 (40) |
| Intermittent | 1 (5) |
| Inconstant | 5 (20) |
| Constant | 6 (30) |
| Visual acuity (Snellen), mean (SD) [range] | 18.6/20 (2.4/20) [12/20-20/20] |
Abbreviations: FT3, free triiodothyronine; GC, glucocorticoid; GO, Graves orbitopathy; IQR, interquartile range; TRAbs, anti-thyrotropin (TSH) receptor antibodies.
SI conversion factor: To convert FT3 to picomoles per liter, multiply by
0.0154.
a
Range, 0 to 7; GO active for clinical activity score values of 3 or higher.